23 active trials 12 recruiting 7 Phase 3 9 disease areas 15 changes in 30 days
10 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 9 with minor changes only.
Recruitment opened
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyPhase 1 NCT07840612 Registry history of NCT07840612 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Primary completion date changed from estimate of Jun 14, 2026 to Aug 11, 2026
EMD Serono Research & Development Institute, Inc.Phase 2 NCT06433219 Registry history of NCT06433219 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Primary completion date changed from estimate of Sep 30, 2026 to Jul 15, 2026
EMD Serono Research & Development Institute, Inc.Phase 1/2 NCT05882734 Registry history of NCT05882734 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Primary completion date changed from estimate of Jan 14, 2027 to Jul 14, 2026
EMD Serono Research & Development Institute, Inc.Phase 1 NCT05396833 Registry history of NCT05396833 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Aug 21, 2026 to Nov 24, 2026
EMD Serono Research & Development Institute, Inc.Phase 3 NCT03815643 Registry history of NCT03815643 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 66 → 92 locations
EMD Serono Research & Development Institute, Inc.Phase 3 NCT07549412 Registry history of NCT07549412 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 36 → 57 locations
And 1 more change in the last 30 days
EMD Serono Research & Development Institute, Inc.Phase 3 NCT07355218 Registry history of NCT07355218 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 45 → 60 locations
EMD Serono Research & Development Institute, Inc.Phase 3 NCT07332481 Registry history of NCT07332481 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment increased: 52 → 65 participants
EMD Serono Research & Development Institute, Inc.Phase 1 NCT06641908 Registry history of NCT06641908 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 148 → 153 locations
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyPhase 3 NCT06463587 Registry history of NCT06463587 on ClinicalTrials.gov (opens the registry)
Updated
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-09-25 | NCT07840287 A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With… | Phase 3 | Not Yet Recruiting |
| 2026-09-25 | NCT07840612 A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and… | Phase 1 | Recruiting |
| Phase 1 | 9 | |
| Phase 1/2 | 1 | |
| Phase 2 | 4 | |
| Phase 3 | 7 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT07549412 | A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to… | Metastatic Colorectal Cancer | Recruiting | 2026-10-08 |
| NCT07332481 | A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or… | Systemic Lupus Erythematosus (SLE) | Recruiting | 2026-10-06 |
| NCT07355218 | A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or… | Systematic Lupus Erythematosus | Recruiting | 2026-10-06 |
| NCT06463587 | Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in… | Generalized Myasthenia Gravis | Recruiting | 2026-09-16 |
| NCT07340827 | A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG… | Infertility | Recruiting | 2026-09-08 |
| NCT07840287 | A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With… | Systemic Lupus Erythematosus (SLE) | Not Yet Recruiting | 2026-09-25 |
| NCT03815643 | Avelumab Program Rollover Study | Solid Tumors | Active, Not Recruiting | 2026-09-22 |
| Phase 2 | ||||
| NCT07499362 | Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT)… | Tenosynovial Giant Cell Tumor | Recruiting | 2026-09-10 |
| NCT05327530 | A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in… | Locally Advanced or Metastatic Urothelial Carcinoma | Active, Not Recruiting | 2026-09-28 |
| NCT05540327 | The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE) | Systemic Lupus Erythematosus | Active, Not Recruiting | 2026-07-20 |
| NCT02864992 | Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) | Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification | Active, Not Recruiting | 2026-07-14 |
| Phase 1/2 | ||||
| NCT06710132 | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE… | Solid Tumors | Active, Not Recruiting | 2026-07-30 |
| Phase 1 | ||||
| NCT07840612 | A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and… | Healthy | Recruiting | 2026-10-09 |
| NCT06641908 | Anti-GD2 ADC M3554 in Advanced Solid Tumors | Advanced Solid Tumor | Recruiting | 2026-10-07 |
| NCT07166601 | M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in… | Advanced Solid Tumor | Recruiting | 2026-10-07 |
| NCT07360314 | Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | 2026-09-29 |
| NCT06577337 | Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participants | Healthy | Recruiting | 2026-09-21 |
| NCT06421935 | M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) | Advanced Solid Tumor | Active, Not Recruiting | 2026-09-09 |
| NCT04170153 | Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid… | Metastatic or Locally Advanced Unresectable Solid Tumors | Active, Not Recruiting | 2026-08-13 |
| NCT06806046 | Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors | Solid Tumors | Active, Not Recruiting | 2026-08-11 |
| NCT05464030 | Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) | Colorectal Cancer | Active, Not Recruiting | 2026-07-30 |
| Not specified | ||||
| NCT05376891 | Met Non Small Cell Cancer Registry (MOMENT) | Cancer | Recruiting | 2026-10-02 |
| NCT05797740 | Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA) | Multiple Sclerosis | Active, Not Recruiting | 2026-08-07 |
Lupus (SLE) (4) · Colorectal Cancer (3) · Lung Cancer (2) · Non-Small Cell Lung Cancer (NSCLC) (2) · Bladder Cancer (1) · Gastric Cancer (1) · Multiple Sclerosis (1) · Myasthenia Gravis (1) · Pancreatic Cancer (1)